BG51358A3 - Метод за получаване на рекомбинантен пнеумолизин и приложението му - Google Patents

Метод за получаване на рекомбинантен пнеумолизин и приложението му Download PDF

Info

Publication number
BG51358A3
BG51358A3 BG094614A BG9461491A BG51358A3 BG 51358 A3 BG51358 A3 BG 51358A3 BG 094614 A BG094614 A BG 094614A BG 9461491 A BG9461491 A BG 9461491A BG 51358 A3 BG51358 A3 BG 51358A3
Authority
BG
Bulgaria
Prior art keywords
zeg
azr
agd
tug
wow
Prior art date
Application number
BG094614A
Other languages
Bulgarian (bg)
English (en)
Inventor
James Paton
David Hansman
Graham Boulnois
Peter Andrew
Timothy Mitchell
John Walker
Original Assignee
David Hansman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David Hansman filed Critical David Hansman
Publication of BG51358A3 publication Critical patent/BG51358A3/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Exchange Systems With Centralized Control (AREA)
  • Manufacturing Of Steel Electrode Plates (AREA)
  • Current-Collector Devices For Electrically Propelled Vehicles (AREA)
BG094614A 1988-12-16 1991-06-12 Метод за получаване на рекомбинантен пнеумолизин и приложението му BG51358A3 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPJ198988 1988-12-16
PCT/AU1989/000539 WO1990006951A1 (en) 1988-12-16 1989-12-15 Pneumolysin mutants and pneumococcal vaccines made therefrom

Publications (1)

Publication Number Publication Date
BG51358A3 true BG51358A3 (bg) 1993-04-15

Family

ID=3773589

Family Applications (1)

Application Number Title Priority Date Filing Date
BG094614A BG51358A3 (bg) 1988-12-16 1991-06-12 Метод за получаване на рекомбинантен пнеумолизин и приложението му

Country Status (15)

Country Link
EP (1) EP0449856B1 (de)
JP (1) JP3237842B2 (de)
AT (1) ATE205534T1 (de)
AU (1) AU626961B2 (de)
BG (1) BG51358A3 (de)
CA (1) CA2005704C (de)
DE (1) DE68929323T2 (de)
DK (1) DK173629B1 (de)
ES (1) ES2160570T3 (de)
FI (1) FI103122B (de)
HU (1) HUT58804A (de)
MC (1) MC2178A1 (de)
NO (1) NO304317B1 (de)
RU (1) RU2121481C1 (de)
WO (1) WO1990006951A1 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716432B1 (en) * 1988-12-16 2004-04-06 James Cleland Paton Pneumolysin mutants and pneumococcal vaccines made therefrom
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
US5391712A (en) * 1991-08-30 1995-02-21 Beckman Instruments, Inc. Non-hemolytic streptolysin O variants
US5928900A (en) * 1993-09-01 1999-07-27 The Rockefeller University Bacterial exported proteins and acellular vaccines based thereon
EP0687688A1 (de) * 1993-12-17 1995-12-20 Universidad De Oviedo Antikörper gegen neumolysin und ihre verwendung
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
AU740956B2 (en) * 1997-07-21 2001-11-15 Baxter Healthcare Sa Modified immunogenic pneumolysin compositions as vaccines
GB9906437D0 (en) * 1999-03-19 1999-05-12 Smithkline Beecham Biolog Vaccine
CA2366152A1 (en) * 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
CN1674933B (zh) 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
CA2503871C (en) 2002-11-01 2012-12-11 Glaxosmithkline Biologicals S.A. An immunogenic composition for generating an immune response against polio virus
CN100443116C (zh) 2002-11-07 2008-12-17 新纳几美国公司 治疗或预防肺炎球菌感染的组合物及其用途
MXPA05009579A (es) 2003-03-13 2005-11-17 Glaxosmithkline Biolog Sa Proceso de purificacion para citolisina bacteriana.
US7709009B2 (en) 2003-07-31 2010-05-04 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for streptococcus pyogenes
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
AU2004277342B2 (en) 2003-10-02 2010-12-16 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
US20120027841A1 (en) 2004-01-07 2012-02-02 Biomedical Research Models, Inc. Novel mucosal vaccination approach for herpes simplex virus type-2
WO2005076696A2 (en) * 2004-02-13 2005-08-25 Sanofi Pasteur Limited Pneumolysin derivatives
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
WO2005108419A1 (en) * 2004-05-07 2005-11-17 Lea-Ann Kirkham Mutant cholesterol-binding cytolysin proteins
WO2006078318A2 (en) 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0421083D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
EP1807446A2 (de) 2004-10-08 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Immunogene und therapeutische zusammensetzungen für pyogene streptokokken
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
JP5792920B2 (ja) 2005-12-22 2015-10-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
MX2008009280A (es) 2006-01-17 2008-12-12 Arne Forsgren Una nueva proteina de haemophilus influenzae expuesta en la superficie (proteina e; pe).
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2468300B1 (de) 2006-09-26 2017-12-20 Infectious Disease Research Institute Impfstoffzusammensetzung mit einem synthetischen Adjuvans
CA2664619C (en) 2006-10-12 2012-12-11 Glaxosmithkline Biologicals S.A. Immunogenic compositions comprising an oil-in-water emulsion adjuvant containing a reduced amount of squalene, tocol and an emulsifying agent
EP2433648A3 (de) 2006-10-12 2012-04-04 GlaxoSmithKline Biologicals S.A. Impfstoff mit einem Öl-in-wasser-emulsionshilfsstoff
CN103550764A (zh) 2007-03-02 2014-02-05 葛兰素史密丝克莱恩生物有限公司 疫苗组合物及其在刺激免疫反应中的用途
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
AU2008287286B2 (en) * 2007-04-13 2013-10-10 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
EA200901578A1 (ru) 2007-06-26 2010-08-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US8287885B2 (en) 2007-09-12 2012-10-16 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
NZ586430A (en) 2007-12-21 2012-09-28 Novartis Ag Mutant forms of streptolysin o (slo)
KR20110009157A (ko) 2008-04-16 2011-01-27 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
CN106008679A (zh) * 2008-12-24 2016-10-12 荷兰王国卫生福利和运动部国家公共卫生和环境研究所 修饰的肺炎链球菌溶血素(ply)多肽
EP3017826A1 (de) 2009-03-24 2016-05-11 Novartis AG Kombinationen von meningokkoken-faktor-h-bindenden proteinen und pneumokokken-saccharid-konjugaten
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
KR20120107121A (ko) * 2009-12-22 2012-09-28 사노피 파스퇴르 리미티드 면역원성 조성물
WO2011075822A1 (en) 2009-12-22 2011-06-30 Sanofi Pasteur Limited Immunogenic compositions and related methods
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
EP2544714A1 (de) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Impfstoffzusammensetzung
JP6002659B2 (ja) 2010-04-13 2016-10-05 セルデックス・セラピューティクス・インコーポレイテッド ヒトｃｄ２７に結合する抗体およびその使用
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
US9181308B2 (en) 2011-03-28 2015-11-10 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
KR20140033127A (ko) 2011-05-17 2014-03-17 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애에 대한 백신
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
EP2941269B1 (de) 2013-01-07 2020-12-09 Mucosal Vaccine Technologies LLC Therapeutische impfstoffe zur behandlung von herpes-simplex-virus-typ 2-infektionen
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US11207396B2 (en) 2013-05-17 2021-12-28 The Board Of Regents Of The University Of Texas System Immunization to protect against adverse cardiac events relating to pneumococcal infection
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
ES2993430T3 (en) 2014-11-21 2024-12-30 Univ Oklahoma Pneumolysin mutants and methods of use thereof
WO2016145085A2 (en) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017176076A1 (en) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation A peptide with ability to penetrate cell membrane
BR112018071307A2 (pt) 2016-04-18 2019-02-26 Celldex Therapeutics, Inc. anticorpos agonistas que ligam cd40 humana e usos dos mesmos
RU2761870C2 (ru) 2016-05-16 2021-12-13 Инфекшес Дизис Рисёрч Инститьют Состав, содержащий агонист tlr, и способы применения
KR102483033B1 (ko) 2016-05-16 2022-12-30 액세스 투 어드밴스드 헬스 인스티튜트 페길화된 리포솜 및 이의 용도
EP3463300A1 (de) 2016-06-01 2019-04-10 Infectious Disease Research Institute Nanoalum-partikel mit einem leimungsmittel
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
AU2018285694B2 (en) 2017-06-15 2025-04-10 Access To Advanced Health Institute Nanostructured lipid carriers and stable emulsions and uses thereof
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
EP3678695A1 (de) 2017-09-08 2020-07-15 Infectious Disease Research Institute Liposomale formulierungen enthaltend saponin und verwendungsverfahren
KR20210011919A (ko) 2018-04-17 2021-02-02 셀덱스 쎄라퓨틱스, 인크. 항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
US20220016168A1 (en) 2018-12-11 2022-01-20 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
JP7551618B2 (ja) 2018-12-12 2024-09-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｏ－結合型グリコシル化のための修飾キャリアタンパク質
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
EP3900739A1 (de) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetische streptococcus-pneumoniae-saccharid-konjugate zum konservierten membranprotein
EP3919076A1 (de) 2020-06-02 2021-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetische oligosaccharidimpfstoffe gegen streptococcus pneumoniae mit mikropartikel-adjuvans-formulierungen
US20230310323A1 (en) 2020-09-04 2023-10-05 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
CN117545773A (zh) 2021-04-09 2024-02-09 塞德斯医疗公司 抗ilt4的抗体、双特异性抗ilt4/pd-l1抗体及其用途
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
EP4433080A1 (de) 2021-11-18 2024-09-25 Matrivax, Inc. Immunogene fusionsproteinzusammensetzungen und verfahren zur verwendung davon
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2495939B1 (fr) * 1980-12-11 1985-10-11 Merieux Inst Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies
DE69428854T2 (de) * 1993-09-03 2002-04-11 Societe Des Produits Nestle S.A., Vevey Bacteriocine aus Streptococcus thermophilus

Also Published As

Publication number Publication date
HUT58804A (en) 1992-03-30
FI912878A0 (fi) 1991-06-14
ATE205534T1 (de) 2001-09-15
DK173629B1 (da) 2001-05-14
EP0449856B1 (de) 2001-09-12
ES2160570T3 (es) 2001-11-16
NO912226D0 (no) 1991-06-11
WO1990006951A1 (en) 1990-06-28
DE68929323D1 (de) 2001-10-18
CA2005704C (en) 2003-02-11
DK115591A (da) 1991-08-14
DK115591D0 (da) 1991-06-14
EP0449856A4 (en) 1992-05-20
JP3237842B2 (ja) 2001-12-10
EP0449856A1 (de) 1991-10-09
FI103122B1 (fi) 1999-04-30
RU2121481C1 (ru) 1998-11-10
NO304317B1 (no) 1998-11-30
CA2005704A1 (en) 1990-06-16
AU4756490A (en) 1990-07-10
DE68929323T2 (de) 2002-04-18
JPH04503948A (ja) 1992-07-16
AU626961B2 (en) 1992-08-13
NO912226L (no) 1991-07-25
FI103122B (fi) 1999-04-30
MC2178A1 (fr) 1992-05-22

Similar Documents

Publication Publication Date Title
EP0449856B1 (de) Pneumolysin-mutanten und pneumokokken-impfstoffe daraus
JPH10504717A (ja) 肺炎双球菌感染症に対する免疫化のための肺炎双球菌多糖−組み換えニューモリシン結合体ワクチン類
CN114667343A (zh) 大肠杆菌组合物及其方法
CN112566658A (zh) 大肠杆菌组合物及其方法
CA2365915C (en) Recombinant toxin a/toxin b vaccine against clostridium difficile
US20230322871A1 (en) Expression of pneumococcal surface protein a (pspa)
US5352450A (en) Method for preparing vaccine for dental caries and vaccinal compositions for dental caries used as nasal drop
US5928650A (en) Subunit vaccine against Neisseria meningitidis infections and corresponding subunits in the purified state
CN108774628A (zh) 合成致新生儿脑膜炎大肠杆菌糖蛋白结合疫苗的大肠杆菌工程菌及用途
GB2602562A (en) CRA4S1 gene, encoded CRA4S1 protein, and application
RU2422524C1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДА, ШТАММ Escherichia coli, ХИМЕРНЫЙ БЕЛОК И ИХ ПРИМЕНЕНИЕ
RU2422525C1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДА, ШТАММ Escherichia coli, ХИМЕРНЫЙ БЕЛОК И ИХ ПРИМЕНЕНИЕ
Chen et al. A nontoxic Pseudomonas exotoxin A induces active immunity and passive protective antibody against Pseudomonas exotoxin A intoxication
JP7303791B2 (ja) スーパー抗原トキソイドに由来する融合ペプチドを含む免疫原性組成物
Armes et al. The complete primary structure of pilin from Haemophilus influenzae type b strain Eagan
KR101908590B1 (ko) Crm197의 용해성 단백질 발현 및 정제 방법
RU2546875C1 (ru) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА CFP10-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pCFP10-DBD, ШТАММ Escherichia coli [pREP4, pCFP10-DBD], ХИМЕРНЫЙ БЕЛОК CFP10-DBD И ИХ ПРИМЕНЕНИЕ
Wahlström et al. The Expression of an Escherichia coli OmpA-Neisseria meningitidis Class
RU2520078C1 (ru) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
RU2520737C1 (ru) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА pESAT6-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pESAT6-DBD, ШТАММ Escherichia coli, ХИМЕРНЫЙ БЕЛОК ESAT6-DBD И ИХ ПРИМЕНЕНИЕ
HK40049582A (en) Escherichia coli compositions and methods thereof
Cho et al. Active Immunity and Passive Protective Antibody against Pseudomonas Exotoxin A Intoxication
OA20033A (en) Expression of Pneumococcal Surface Protein A (PSPA).
JPH0368522A (ja) う蝕ワクチンの製造法